Laboratory diagnosis and management challenges in the antiphospholipid syndrome

被引:31
作者
Bertolaccini, ML [1 ]
Khamashta, MA [1 ]
机构
[1] St Thomas Hosp, Rayne Inst, Kings Coll London Sch Med, Lupus Res Unit,Guys Kings & St Thomas Hosp, London SE1 7EH, England
关键词
anticardiolipin; heparin; lupus anticoagulant; pregnancy morbidity; thrombosis; warfarin;
D O I
10.1191/0961203306lu2293rr
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The antiphospholipid syndrome (APS) is characterized by recurrent arterial and/or venous thrombosis and pregnancy morbidity manifested by early or late losses. Laboratory diagnosis of APS relies on the demonstration of a positive test for antiphospholipid antibodies (aPL). In clinical practice, the gold standard tests are those that detect anticardiolipin antibodies (aCL) and/or the lupus anticoagulant ( LA). Although other specificities for aPL have been described their clinical utility and standardization has still to be established. Persistence of aPL positive tests must be demonstrated, and other causes and underlying factors considered. Although it is universally recognized that the routine screening tests ( aCL and/or LA) might miss some cases, careful differential diagnosis and repeat testing are mandatory before the diagnosis of 'seronegative APS' can be made. Correct identification of patients with APS is important, because prophylactic anticoagulant therapy can prevent thrombosis from recurring, and treatment of affected women during pregnancy can improve fetal and maternal outcome.
引用
收藏
页码:172 / 178
页数:7
相关论文
共 93 条
  • [1] Amengual O, 1996, BRIT J RHEUMATOL, V35, P1239
  • [2] Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines
    Asherson, RA
    Cervera, R
    de Groot, PG
    Erkan, D
    Boffa, MC
    Piette, JC
    Khamashta, MA
    Shoenfeld, Y
    [J]. LUPUS, 2003, 12 (07) : 530 - 534
  • [3] Atsumi T, 1998, CLIN EXP IMMUNOL, V112, P325
  • [4] ANTI-BETA(2)-GLYCOPROTEIN-I ANTIBODIES - A MARKER OF ANTIPHOSPHOLIPID SYNDROME
    BALESTRIERI, G
    TINCANI, A
    SPATOLA, L
    ALLEGRI, F
    PRATI, E
    CATTANEO, R
    VALESINI, G
    DELPAPA, N
    MERONI, P
    [J]. LUPUS, 1995, 4 (02) : 122 - 130
  • [5] BEAUMONT J L, 1954, Sang, V25, P1
  • [6] Antiphospholipid antibody tests: spreading the net
    Bertolaccini, ML
    Gomez, S
    Pareja, JFP
    Theodoridou, A
    Sanna, G
    Hughes, GRV
    Khamashta, MA
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 (11) : 1639 - 1643
  • [7] Antiprothrombin antibodies detected in two different assay systems - Prevalence and clinical significance in systemic lupus erythematosus
    Bertolaccini, ML
    Atsumi, T
    Koike, T
    Hughes, GRV
    Khamashta, MA
    [J]. THROMBOSIS AND HAEMOSTASIS, 2005, 93 (02) : 289 - 297
  • [8] Antibodies directed to protein S in patients with systemic lupus erythematosus: prevalence and clinical significance
    Bertolaccini, ML
    Sanna, G
    Ralhan, S
    Gennari, LC
    Merrill, JT
    Khamashta, MA
    Hughes, GRV
    [J]. THROMBOSIS AND HAEMOSTASIS, 2003, 90 (04) : 636 - 641
  • [9] Bertolaccini ML, 2001, J RHEUMATOL, V28, P2637
  • [10] BOWIE EJW, 1963, J LAB CLIN MED, V62, P416